Financial News

Financial Report: Mylan

$465 million DoJ settlement hits earnings

By: Kristin Brooks

Managing Editor, Contract Pharma

Mylan

3Q Revenues: $3.1 billion (+13%)

3Q Loss: $119.8 million (earnings were $428.6 million 3Q15)

YTD Revenues: $7.8 billion (+13%)

YTD Earnings: $62.5 million (earnings were $653.1 million YTD15)

Comments: Generics segment third party sales in the quarter were $2.6 billion, up 17%. Specialty segment sales were $418.7 million, down 4%. Loss in the quarter was primarily a result of the company’s $465 million settlement with the U.S. Department of Justice and other government agencies related to the classification of the EpiPen for purposes of the Medicaid Drug Rebate Program.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters